Pursuits
Cancer Drug Once Bought for $7 Million May Now Fetch $18 Billion
Blood sample from a patient with lymphocytic leukaemia (CLL).
Photographer: Brand X Pictures/Getty ImagesThis article is for subscribers only.
An overlooked drug bought by a biotech company for a mere $6.6 million a decade ago could become one of the biggest selling cancer treatments ever.
Those high expectations have its maker, Pharmacyclics Inc., considering selling itself in a deal that could be worth as much as $18 billion.